CA3070747A1 - Chemically modified oligonucleotides - Google Patents
Chemically modified oligonucleotides Download PDFInfo
- Publication number
- CA3070747A1 CA3070747A1 CA3070747A CA3070747A CA3070747A1 CA 3070747 A1 CA3070747 A1 CA 3070747A1 CA 3070747 A CA3070747 A CA 3070747A CA 3070747 A CA3070747 A CA 3070747A CA 3070747 A1 CA3070747 A1 CA 3070747A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- nucleic acid
- chemically
- double stranded
- rxrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542043P | 2017-08-07 | 2017-08-07 | |
| US62/542,043 | 2017-08-07 | ||
| US201762558183P | 2017-09-13 | 2017-09-13 | |
| US62/558,183 | 2017-09-13 | ||
| PCT/US2018/045671 WO2019032619A1 (en) | 2017-08-07 | 2018-08-07 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3070747A1 true CA3070747A1 (en) | 2019-02-14 |
Family
ID=65271710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3070747A Pending CA3070747A1 (en) | 2017-08-07 | 2018-08-07 | Chemically modified oligonucleotides |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200215113A1 (https=) |
| EP (1) | EP3664817A4 (https=) |
| JP (2) | JP7820909B2 (https=) |
| CN (1) | CN111201024A (https=) |
| AU (1) | AU2018313149B2 (https=) |
| CA (1) | CA3070747A1 (https=) |
| WO (1) | WO2019032619A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2746527A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
| WO2015084897A2 (en) * | 2013-12-02 | 2015-06-11 | Mirimmune, Llc | Immunotherapy of cancer |
| US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
| KR102506169B1 (ko) | 2014-09-05 | 2023-03-08 | 피오 파마슈티칼스 코프. | Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법 |
| CN108135923B (zh) | 2015-07-06 | 2021-03-02 | 菲奥医药公司 | 靶向超氧化物歧化酶1（sod1）的核酸分子 |
| WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| WO2018195355A1 (en) | 2017-04-19 | 2018-10-25 | Rxi Pharmaceuticals Corporation | Topical delivery of nucleic acid compounds |
| CN115135765A (zh) * | 2019-11-08 | 2022-09-30 | 菲奥医药公司 | 用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸 |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| CN112266911B (zh) * | 2020-08-27 | 2022-07-22 | 清华大学 | 核酸分子 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| WO2023015264A1 (en) * | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
| JP2024529025A (ja) | 2021-08-04 | 2024-08-01 | フィオ ファーマシューティカルズ コーポレーション | 化学修飾されたオリゴヌクレオチド |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| WO2023130021A1 (en) * | 2021-12-30 | 2023-07-06 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved delivery properties |
| EP4537107A2 (en) | 2022-06-07 | 2025-04-16 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| WO2024064769A1 (en) * | 2022-09-21 | 2024-03-28 | Phio Pharmaceuticals Corp. | Induction of stem-like activated t cells |
| WO2025101204A1 (en) * | 2023-11-08 | 2025-05-15 | Phio Pharmaceuticals Corp. | Intratumoral targeting of pd-1 |
| WO2025117786A1 (en) * | 2023-11-28 | 2025-06-05 | Phio Pharmaceuticals Corp. | Enhanced combination immune checkpoint inhibition therapy utilizing rnai |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CA2746527A1 (en) * | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| US8691971B2 (en) * | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| US9745574B2 (en) * | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| US9957558B2 (en) * | 2011-04-28 | 2018-05-01 | Life Technologies Corporation | Methods and compositions for multiplex PCR |
| WO2015084897A2 (en) * | 2013-12-02 | 2015-06-11 | Mirimmune, Llc | Immunotherapy of cancer |
| CA2958200A1 (en) * | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
| WO2016177343A1 (zh) * | 2015-05-05 | 2016-11-10 | 江苏命码生物科技有限公司 | 一种新的前体miRNA及其在肿瘤治疗中的应用 |
| EP3349792A1 (en) * | 2015-09-14 | 2018-07-25 | Compass Therapeutics LLC | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- |
-
2018
- 2018-08-07 JP JP2020506983A patent/JP7820909B2/ja active Active
- 2018-08-07 US US16/637,514 patent/US20200215113A1/en active Pending
- 2018-08-07 CN CN201880061531.8A patent/CN111201024A/zh active Pending
- 2018-08-07 AU AU2018313149A patent/AU2018313149B2/en active Active
- 2018-08-07 CA CA3070747A patent/CA3070747A1/en active Pending
- 2018-08-07 EP EP18843248.8A patent/EP3664817A4/en active Pending
- 2018-08-07 WO PCT/US2018/045671 patent/WO2019032619A1/en not_active Ceased
-
2023
- 2023-09-11 JP JP2023146785A patent/JP2024028231A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3664817A1 (en) | 2020-06-17 |
| AU2018313149B2 (en) | 2024-11-14 |
| JP2024028231A (ja) | 2024-03-01 |
| WO2019032619A1 (en) | 2019-02-14 |
| AU2018313149A1 (en) | 2020-03-05 |
| CN111201024A (zh) | 2020-05-26 |
| JP2020532955A (ja) | 2020-11-19 |
| EP3664817A4 (en) | 2021-09-22 |
| WO2019032619A9 (en) | 2020-02-13 |
| JP7820909B2 (ja) | 2026-02-26 |
| US20200215113A1 (en) | 2020-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018313149B2 (en) | Chemically modified oligonucleotides | |
| AU2018202014B2 (en) | Rna interference in dermal and fibrotic indications | |
| JP2018502837A (ja) | 遺伝子調節アプローチを用いた円形脱毛症の処置方法 | |
| CA2991598A1 (en) | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) | |
| CA2932753A1 (en) | Methods for treatment of wound healing utilizing chemically modified oligonucleotides | |
| WO2017007825A1 (en) | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach | |
| US20230002766A1 (en) | Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy | |
| WO2023130021A1 (en) | Chemically modified oligonucleotides with improved delivery properties | |
| US20240301430A1 (en) | Chemically modified oligonucleotides | |
| WO2023015264A1 (en) | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides | |
| US20230089478A1 (en) | Chemically modified oligonucleotides with improved systemic delivery | |
| US20260097120A1 (en) | Induction of stem-like activated t cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220914 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240802 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240802 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240802 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241002 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250220 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250521 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250521 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250801 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250829 |